Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study

  • Reto Widrig
  • Andy Suter
  • Reinhard Saller
  • Jörg MelzerEmail author
Original Article


The use of topical preparations for symptom relief is common in osteoarthritis. The effects of ibuprofen (5%) and arnica (50 g tincture/100 g, DER 1:20), as gel preparations in patients with radiologically confirmed and symptomatically active osteoarthritis of interphalangeal joints of hands, were evaluated in a randomised, double-blind study in 204 patients, to ascertain differences in pain relief and hand function after 21 days’ treatment. Diagnosis was according to established criteria; primary endpoints were pain intensity and hand function; statistical design was as per current regulatory guidelines for testing topical preparations. There were no differences between the two groups in pain and hand function improvements, or in any secondary end points evaluated. Adverse events were reported by six patients (6.1%) on ibuprofen and by five patients (4.8%) on arnica. Our results confirm that this preparation of arnica is not inferior to ibuprofen when treating osteoarthritis of hands.


Osteoarthritis Ibuprofen gel Arnica gel Randomised trial Gel treatment 



RS conceived the overall project plan. RW was the Principal Investigator. The following doctors treated and evaluated patients in the 20 study clinics: D. Kähler (Wil); R. Widrig (St Gallen); D. Geiger (Au); S. Bachmann (Valens); H. Martin (Gossau); M. Burla (Zürich); B. Kindler (Zürich); M. Senn (Zürich); U. Aufdenblatten (Zürich); H. Sajdl (Zürich); K. Grimm (Dietikon); E. Zeley-Zimonyi (Zürich); M. Steigbügel (Wald); U. Pachlatko (Ebmatingen); M. Tejero (Baden); B. Haldemann (Küttigen); H. Maurer (St Gallen); F. Akermann (Buchs); F. Jaggi (Zürich); A. Stevka (Zürich); H. Steinemann (St Gallen). Statistical analysis was conducted by DSH Statistical Services GmbH, Germany.


  1. 1.
    Zhang Y, Niu J, Kelly-Hayes M et al (2002) Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: the Framingham Study. Am J Epidemiol 156:1021–1027PubMedCrossRefGoogle Scholar
  2. 2.
    Hochberg MC, Vignon E, Maheu E (2000) Clinical assessment of hand OA. Osteoarthr Cartil 8(Suppl A):S38–S40PubMedGoogle Scholar
  3. 3.
    Stamm TA, Machold KP, Smolen JS et al (2002) Joint protection and home hand exercises improve hand function in patients with hand osteoarthritis: a randomized controlled trial. Arthritis Rheum 47:44–49PubMedCrossRefGoogle Scholar
  4. 4.
    Moore N (2003) Forty years of ibuprofen use. Int J Clin Pract 135(Suppl Apr):28–31Google Scholar
  5. 5.
    Heyneman CA, Lawless-Liday C, Wall GC (2000) Oral versus topical NSAIDs in rheumatic diseases. Drugs 60:555–574PubMedCrossRefGoogle Scholar
  6. 6.
    Moore RA, Tramèr MR, Carroll D et al (1998) Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 316:333–338PubMedGoogle Scholar
  7. 7.
    Ramesh N, Steuber U (1983) Dolgit® cream in accident- and sports-related injuries in medical practice. Results of a double blind study. Therapiewoche 33:4563–4570Google Scholar
  8. 8.
    Machen J, Whitefield M (2002) Efficacy of a proprietary ibuprofen gel in soft tissue injuries: a randomised, double-blind, placebo-controlled study. Int J Clin Pract 56:102–106PubMedGoogle Scholar
  9. 9.
    Dreiser RL (1988) Clinical trial of efficacy and tolerability of topical ibuprofen in the treatment of tendonitis. Le J Int Méd 119:15–31Google Scholar
  10. 10.
    Nasonova VA Muravyev IuV, Nasonov EL et al (1995) Local application of dolgit cream in patients with osteoarthritis: multicentre study of efficacy and tolerance. Ter Arkh 67:48–50Google Scholar
  11. 11.
    Guillaume M (1988) Clinical study on the efficacy and tolerability of percutaneous ibuprofen for the symptomatic treatment of arthrosis of small joints. Etude clinique de l’efficacité et de la tolérance de l’ibuprofène percutané dans le traitement symptomatique de l’arthrose des petites articulations. J Intern Med 2:1–4Google Scholar
  12. 12.
    Trnavsky K, Fischer M, Voegtle-Junkert U, Schreyger F (2004) Efficacy and safety of 5% ibuprofen cream treatment in knee osteoarthritis. Results of a randomized, double-blind, placebo-controlled study. J Rheumatol 31:565–572PubMedGoogle Scholar
  13. 13.
    Dominkus M, Nicolakis M, Kotz R et al (1996) Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittelforschung 46:1138–1143PubMedGoogle Scholar
  14. 14.
    Steen AE, Reeh PW, Geisslinger G et al (2004) Plasma levels after peroral and topical ibuprofen and effects upon low pH induced cutaneous and muscle pain. Eur J Pain 4:195–209CrossRefGoogle Scholar
  15. 15.
    Ernst E (2004) Musculoskeletal conditions and complementary/alternative medicine. Best Pract Res Clin Rheumatol 18:539–556PubMedCrossRefGoogle Scholar
  16. 16.
    Mayer JG et al (2000) Arnica montana or Mountain Arnica—a cultural–historical essay and on the problems of writing such an essay. Arnica montana L., oder Bergwohlverleih – Ein kulturhistorischer Essay – und über die Schwierigkeiten einen solchen zu verfassen. Zeitschrift für Phytotherapie 21:30–36Google Scholar
  17. 17.
    Knuesel O, Weber M, Suter A (2002) Arnica montana gel in osteoarthritis of the knee: an open, multicentre clinical trial. Adv Ther 19:209–218PubMedGoogle Scholar
  18. 18.
    Lyss G, Schmidt TJ, Merfort I et al (1997) Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF-KappaB. Biol Chem 378:951–961PubMedCrossRefGoogle Scholar
  19. 19.
    De Bosscher K, Vanden Berghe W, Vermeulen L et al (2000) Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Nat Acad Sci 97:3919–3924PubMedCrossRefGoogle Scholar
  20. 20.
    Wagner S, Suter A, Merfort I (2004) Skin penetration studies of Arnica preparations and of their sesquiterpene lactones. Planta Med 70:897–903PubMedCrossRefGoogle Scholar
  21. 21.
    Altman R, Alarcon G, Appelrouth D et al (1990) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 33:1601–1610PubMedCrossRefGoogle Scholar
  22. 22.
    Lequesne MG, Maheu E (2000) Methodology of clinical trials in hand osteoarthritis: conventional and proposed tools. Osteoarthr Cartil 8(Suppl A):S64–S69PubMedGoogle Scholar
  23. 23.
    European Medicines Agency (EMEA) Guideline on the choice of non-inferiority margin. [Document locator: CPMP/EWP/2158/99]. Available from: (Accessed: 25.04.06)
  24. 24.
    European Medicines Agency (EMEA) Note for Guidance on Choice of Control Groups in Clinical Trials. (Document locator: CPMP/ICH/364/96). Available from: (Accessed: 25.04.06)
  25. 25.
    Dreiser RL, Maheu E, Guillou GB et al (1995) Validation of an algofunctional index for osteoarthritis of the hand. Rev Rhum Engl Ed 62(6 Suppl 1):S43–S53Google Scholar
  26. 26.
    Vaile J, Davis P (1998) Topical NSAIDs for musculoskeletal conditions. A review of the literature. Drugs 56:783–799PubMedCrossRefGoogle Scholar
  27. 27.
    Lin J, Zhand W, Jones A, Doherty M (2004) Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 329(7461):324PubMedCrossRefGoogle Scholar
  28. 28.
    Cooper C (2004) Topical NSAIDs in osteoarthritis. BMJ 329:304–305PubMedCrossRefGoogle Scholar
  29. 29.
    Whitefield M, O’Kane CJA (2002) Comparative efficacy of a proprietary topical ibuprofen gel and oral ibuprofen in acute soft tissue injuries: a randomized, double-blind study. J Clin Pharm Ther 27:409–417PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Reto Widrig
    • 1
  • Andy Suter
    • 2
  • Reinhard Saller
    • 3
  • Jörg Melzer
    • 3
    Email author
  1. 1.Rheumatology ClinicSt GallenSwitzerland
  2. 2.Bioforce AGRoggwilSwitzerland
  3. 3.Department of Internal Medicine, Institute of Complementary MedicineUniversity Hospital ZurichZurichSwitzerland

Personalised recommendations